Clinical trials: Colorectal Cancer Metastatic to Liver
Genomic Instability, Prognostic Cancer Model
Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases
A retrospective cohort of 286 patients with synchronous CRLM underwent conversion therapies based on next-generation sequencing (NGS) results.
- Trial name
- NCT06477718
- Volunteers
- 286 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Sinusoidal Obstruction Syndrome, Colorectal Liver Metastases
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
The purpose of the study is to determine whether anticoagulant use (i.e. salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) is able to prevent the development of the sinusoidal obstruction syndrome…
- Trial name
- NCT00885950
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Colorectal Carcinoma Metastatic in the Liver
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals…
- Trial name
- METEORITE (NCT06555133)
- Testing
- yttrium-90 radioembolization
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Long-term Oncologic Outcome of MILS in Patients With CRLM and Prognostic Indicators
Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors
Only few reports exist on long-term survival after minimally invasive liver surgery (MILS for colorectal liver metastases. No data are available assessing prognostic factors in the era of current modern treatment strategies.
- Trial name
- NCT01356706
- Where
- Belgium
- Volunteers
- 274 people
- Sponsor
- University Hospital, Gasthuisberg
Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis
The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care…
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer, Liver Metastases From Colorectal Cancer, Liver Metastases of Colorectal Cancer
- Trial name
- HAIP-6192 (NCT07764497)
- Testing
- Floxuridine (FUDR)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Sunnybrook Health Sciences Centre
Colorectal Cancer, Liver Metastases
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM).
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Cancer
- Trial name
- NCT07044362
- Testing
- HistoSonics Edison® System, Chemotherapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Colorectal Cancer, pMMR
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
The main objective of the SIRTCI study is to evaluate the safety and efficacy of the combination chemotherapy (XELOX: Capecitabine plus oxaliplatin), anti-angiogenic (Bevacizumab), SIRT (TheraSphere®) and ICI (Atezolizumab) in…
- Conditions
- Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor
- Trial name
- SIRTCI (NCT04659382)
- Testing
- Atezolizumab, Therasphere, XELOX
- Where
- 19 sites in France
- Volunteers
- 52 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Colorectal Liver Metastases, Colon Cancer
Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.
The performance of multiple minor hepatectomies (MMH) instead of major hepatectomies (MH) in patients with colorectal liver metastases (CLM) is object of debate.
- Trial name
- NCT02331641
- Testing
- Hepatectomy
- Volunteers
- 554 people
- Sponsor
- University of Milan
Liver Metastases From Colorectal Primary Cancer
Ultrasound Liver Intraoperative Imaging With SonoVue®
Hypothesis: Use of contrast ultrasound showed interesting results, which can increase ultrasonography sensitivity performed during surgery in the evaluation of operable liver metastases.
- Trial name
- ULIIS (NCT01880554)
- Testing
- Contrast-enhanced intraoperative ultrasound
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
CRC
Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM
This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of Candonilimab (AK104) combined with Regorafenib for the treatment of MSS colorectal liver metastasis.
- Trial name
- NCT06455254
- Testing
- Candonilimab (AK104), Regorafenib
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- Jin-hong Chen
Metastatic Colorectal Cancer
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in…
- Trial name
- COLIBRI-GI (NCT07359456)
- Testing
- Ivonescimab, Bevacizumab, FOLFIRI Protocol
- Where
- 22 sites in France
- Volunteers
- 130 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in…
- Trial name
- CELIM2 (NCT01802645)
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 15 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Technische Universität Dresden
Colorectal Cancer, Liver Metastases From Colorectal Cancer
Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis
The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients.
- Conditions
- Colorectal Cancer, Liver Metastases From Colorectal Cancer, Pathology, Exosome
- Trial name
- NCT07177742
- Testing
- Observation
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mu-qing Yang
Colorectal Liver Metastasis
Postoperative Exercise Training in Patients With Colorectal Liver Metastases Undergoing Surgery (ELMA)
Surgery is a primary treatment modality in the intended curative treatment of colorectal liver metastases (CRLM). However, surgery elicits a cascade of potentially detrimental stress responses that may drive the onset of…
- Trial name
- ELMA (NCT04751773)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
CRC (Colorectal Cancer), Melanoma (Skin Cancer)
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with…
- Conditions
- CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- TGI5 (NCT07376707)
- Testing
- TGI-5
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.